Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Treatment of Recurrent Clostridium difficile Diarrhea.

Huebner ES, Surawicz CM.

Gastroenterol Hepatol (N Y). 2006 Mar;2(3):203-208.

2.

Perceptions of fecal microbiota transplantation for Clostridium difficile infection: factors that predict acceptance.

Park L, Mone A, Price JC, Tzimas D, Hirsh J, Poles MA, Malter L, Chen LA.

Ann Gastroenterol. 2017;30(1):83-88. doi: 10.20524/aog.2016.0098. Epub 2016 Oct 20.

3.

Prospective randomized controlled study on the effects of Saccharomyces boulardii CNCM I-745 and amoxicillin-clavulanate or the combination on the gut microbiota of healthy volunteers.

Kabbani TA, Pallav K, Dowd SE, Villafuerte-Galvez J, Vanga RR, Castillo NE, Hansen J, Dennis M, Leffler DA, Kelly CP.

Gut Microbes. 2017 Jan 2;8(1):17-32. doi: 10.1080/19490976.2016.1267890. Epub 2016 Dec 14.

4.

Clostridium difficile Infection and Fecal Microbiota Transplant.

Liubakka A, Vaughn BP.

AACN Adv Crit Care. 2016 Jul;27(3):324-337. Review.

5.

Management of Clostridium difficile Infection.

Al-Jashaami LS, DuPont HL.

Gastroenterol Hepatol (N Y). 2016 Oct;12(10):609-616.

6.

Mortality, Hospital Costs, Payments, and Readmissions Associated With Clostridium difficile Infection Among Medicare Beneficiaries.

Drozd EM, Inocencio TJ, Braithwaite S, Jagun D, Shah H, Quon NC, Broderick KC, Kuti JL.

Infect Dis Clin Pract (Baltim Md). 2015 Nov;23(6):318-323. Epub 2015 Nov 2.

7.
8.

Advances in the Microbiome: Applications to Clostridium difficile Infection.

Culligan EP, Sleator RD.

J Clin Med. 2016 Sep 21;5(9). pii: E83. doi: 10.3390/jcm5090083. Review.

9.

Probiotic Saccharomyces boulardii CNCM I-745 prevents outbreak-associated Clostridium difficile-associated cecal inflammation in hamsters.

Koon HW, Su B, Xu C, Mussatto CC, Tran DH, Lee EC, Ortiz C, Wang J, Lee JE, Ho S, Chen X, Kelly CP, Pothoulakis C.

Am J Physiol Gastrointest Liver Physiol. 2016 Oct 1;311(4):G610-G623. doi: 10.1152/ajpgi.00150.2016. Epub 2016 Aug 11.

10.

Fidaxomicin versus Vancomycin in the Treatment of Clostridium difficile Infection: Canadian Outcomes.

Lee C, Louie TJ, Weiss K, Valiquette L, Gerson M, Arnott W, Gorbach SL.

Can J Infect Dis Med Microbiol. 2016;2016:8048757. doi: 10.1155/2016/8048757. Epub 2016 May 24.

11.

Faecal microbiota transplantation: applications and limitations in treating gastrointestinal disorders.

Sbahi H, Di Palma JA.

BMJ Open Gastroenterol. 2016 May 9;3(1):e000087. doi: 10.1136/bmjgast-2016-000087. eCollection 2016.

12.

Probiotics as adjunctive therapy for preventing Clostridium difficile infection - What are we waiting for?

Spinler JK, Ross CL, Savidge TC.

Anaerobe. 2016 Oct;41:51-57. doi: 10.1016/j.anaerobe.2016.05.007. Epub 2016 May 13. Review.

13.

A Review of Management of Clostridium difficile Infection: Primary and Recurrence.

Vincent Y, Manji A, Gregory-Miller K, Lee C.

Antibiotics (Basel). 2015 Sep 24;4(4):411-23. doi: 10.3390/antibiotics4040411. Review.

14.

Probiotics for the Primary and Secondary Prevention of C. difficile Infections: A Meta-analysis and Systematic Review.

McFarland LV.

Antibiotics (Basel). 2015 Apr 13;4(2):160-78. doi: 10.3390/antibiotics4020160. Review.

15.

Comparison of pediatric and adult antibiotic-associated diarrhea and Clostridium difficile infections.

McFarland LV, Ozen M, Dinleyici EC, Goh S.

World J Gastroenterol. 2016 Mar 21;22(11):3078-104. doi: 10.3748/wjg.v22.i11.3078. Review.

16.

Quantifying Transmission of Clostridium difficile within and outside Healthcare Settings.

Durham DP, Olsen MA, Dubberke ER, Galvani AP, Townsend JP.

Emerg Infect Dis. 2016 Apr;22(4):608-16. doi: 10.3201/eid2204.150455.

17.

Cost-Effectiveness Analysis of Six Strategies to Treat Recurrent Clostridium difficile Infection.

Lapointe-Shaw L, Tran KL, Coyte PC, Hancock-Howard RL, Powis J, Poutanen SM, Hota S.

PLoS One. 2016 Feb 22;11(2):e0149521. doi: 10.1371/journal.pone.0149521. eCollection 2016.

18.

Probiotic Therapy of the Irritable Bowel Syndrome: Why Is the Evidence Still Poor and What Can Be Done About It?

Mazurak N, Broelz E, Storr M, Enck P.

J Neurogastroenterol Motil. 2015 Oct 1;21(4):471-85. doi: 10.5056/jnm15071.

19.

WSES guidelines for management of Clostridium difficile infection in surgical patients.

Sartelli M, Malangoni MA, Abu-Zidan FM, Griffiths EA, Di Bella S, McFarland LV, Eltringham I, Shelat VG, Velmahos GC, Kelly CP, Khanna S, Abdelsattar ZM, Alrahmani L, Ansaloni L, Augustin G, Bala M, Barbut F, Ben-Ishay O, Bhangu A, Biffl WL, Brecher SM, Camacho-Ortiz A, Caínzos MA, Canterbury LA, Catena F, Chan S, Cherry-Bukowiec JR, Clanton J, Coccolini F, Cocuz ME, Coimbra R, Cook CH, Cui Y, Czepiel J, Das K, Demetrashvili Z, Di Carlo I, Di Saverio S, Dumitru IM, Eckert C, Eckmann C, Eiland EH, Enani MA, Faro M, Ferrada P, Forrester JD, Fraga GP, Frossard JL, Galeiras R, Ghnnam W, Gomes CA, Gorrepati V, Ahmed MH, Herzog T, Humphrey F, Kim JI, Isik A, Ivatury R, Lee YY, Juang P, Furuya-Kanamori L, Karamarkovic A, Kim PK, Kluger Y, Ko WC, LaBarbera FD, Lee JG, Leppaniemi A, Lohsiriwat V, Marwah S, Mazuski JE, Metan G, Moore EE, Moore FA, Nord CE, Ordoñez CA, Júnior GA, Petrosillo N, Portela F, Puri BK, Ray A, Raza M, Rems M, Sakakushev BE, Sganga G, Spigaglia P, Stewart DB, Tattevin P, Timsit JF, To KB, Tranà C, Uhl W, Urbánek L, van Goor H, Vassallo A, Zahar JR, Caproli E, Viale P.

World J Emerg Surg. 2015 Aug 20;10:38. doi: 10.1186/s13017-015-0033-6. eCollection 2015. Review.

20.

Probiotic-based strategies for therapeutic and prophylactic use against multiple gastrointestinal diseases.

Varankovich NV, Nickerson MT, Korber DR.

Front Microbiol. 2015 Jul 14;6:685. doi: 10.3389/fmicb.2015.00685. eCollection 2015. Review.

Supplemental Content

Support Center